deltatrials
Completed PHASE1/PHASE2 NCT02024607

A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer

A Phase Ib/II Clinical Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer

Sponsor: Sumitomo Pharma America, Inc.

Conditions Advanced Gastrointestinal Cancer
Interventions BBI608 Bevacizumab Capecitabine Fluorouracil Irinotecan Leucovorin Oxaliplatin Regorafenib
Updated 18 times since 2017 Last updated: Nov 13, 2023 Started: Jan 31, 2014 Primary completion: Mar 31, 2019 Completion: Nov 30, 2019

This PHASE1/PHASE2 trial investigates Advanced Gastrointestinal Cancer and is currently completed. Sumitomo Pharma America, Inc. leads this study, which shows 18 recorded versions since 2014 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Oct 2017 · 8 months · monthly snapshot~Oct 2017 – ~Jun 2018 · 8 months · monthly snapshot~Jun 2018 – ~Oct 2018 · 4 months · monthly snapshot~Oct 2018 – ~Apr 2019 · 6 months · monthly snapshot~Apr 2019 – ~Jul 2019 · 3 months · monthly snapshot~Jul 2019 – ~Feb 2020 · 7 months · monthly snapshot~Feb 2020 – ~Aug 2020 · 6 months · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~Oct 2021 · 9 months · monthly snapshot~Oct 2021 – ~May 2022 · 7 months · monthly snapshot~May 2022 – ~Dec 2022 · 7 months · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Nov 2023 · 10 months · monthly snapshot~Nov 2023 – ~Dec 2023 · 30 days · monthly snapshot~Dec 2023 – ~Jul 2024 · 7 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 19 months · monthly snapshot

Change History

18 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Dec 2023 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  4. Nov 2023 — Dec 2023 [monthly]

    Completed PHASE1_PHASE2

  5. Jan 2023 — Nov 2023 [monthly]

    Completed PHASE1_PHASE2

▶ Show 13 earlier versions

  1. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE1_PHASE2

  2. May 2022 — Dec 2022 [monthly]

    Completed PHASE1_PHASE2

  3. Oct 2021 — May 2022 [monthly]

    Completed PHASE1_PHASE2

  4. Jan 2021 — Oct 2021 [monthly]

    Completed PHASE1_PHASE2

  5. Aug 2020 — Jan 2021 [monthly]

    Completed PHASE1_PHASE2

    Status: Active Not Recruiting → Completed

  6. Feb 2020 — Aug 2020 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  7. Jul 2019 — Feb 2020 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  8. Apr 2019 — Jul 2019 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  9. Oct 2018 — Apr 2019 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  10. Jun 2018 — Oct 2018 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  11. Oct 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  12. Feb 2017 — Oct 2017 [monthly]

    Recruiting PHASE1_PHASE2

  13. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Jan 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Sumitomo Pharma America, Inc.
Data source: Sumitomo Pharma America, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Charleston, United States , Chattanooga, United States , Cincinnati, United States , Fort Myers, United States , Fort Wayne, United States , Goshen, United States , Greenville, United States , Indianapolis, United States , Lafayette, United States and 5 more locations